Cambridge Investment Research Advisors
AVTX icon

Cambridge Investment Research Advisors’s Avalo Therapeutics AVTX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8
Closed -$39K – 3165
2021
Q4 		$39K Buy
8
+4
+100% +$24K ﹤0.01% 3111
2021
Q3 		$27K Hold
4
– – ﹤0.01% 3046
2021
Q2 		$34K Buy
+4
New +$33.5K ﹤0.01% 3045
2020
Q2 		– Sell
-7
Closed -$48K – 2457
2020
Q1 		$48K Buy
7
+1
+17% +$10.6K ﹤0.01% 2183
2019
Q4 		$99K Hold
6
– – ﹤0.01% 2313
2019
Q3 		$61K Sell
6
-1
-14% -$11.2K ﹤0.01% 2264
2019
Q2 		$104K Buy
7
+1
+17% +$15.2K ﹤0.01% 2097
2019
Q1 		$99K Sell
6
-1
-14% -$15K ﹤0.01% 2190
2018
Q4 		$61K Sell
7
-6
-46% -$66.9K ﹤0.01% 2076
2018
Q3 		$169K Buy
+13
New +$170K ﹤0.01% 2085

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Cambridge Investment Research Advisors's AVTX Position: Q1 2022 in Review

Cambridge Investment Research Advisors sold out of Avalo Therapeutics (AVTX) in Q1 2022, closing a stake of 8 shares — an estimated $39K sold.

Cambridge Investment Research Advisors first reported a position in AVTX in Q3 2018 and held it in 10 quarters. The position peaked at $169K in Q3 2018. 65 funds tracked by Wall St. Rank hold AVTX as of Q1 2022.

  • Cambridge Investment Research Advisors reported no remaining Avalo Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 8 Avalo Therapeutics shares in Q1 2022, an estimated $39K.
  • Cambridge Investment Research Advisors first reported a position in Avalo Therapeutics in Q3 2018 and held it in 10 quarters.
  • Cambridge Investment Research Advisors's Avalo Therapeutics position peaked at $169K in Q3 2018.
  • 65 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2022, filed 12 May 2022.